1094 Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices 

(NAMs), to reduce, refine or replace 

vertebrate animal testing and provide 

information of equivalent or better 

scientific quality and relevance for 

assessing risks of injury to health or the 

environment. 

ADDRESSES: The docket for this action, 

identified by docket identification (ID) 

number EPA–HQ–OPPT–2023–0627, is 

available online at http://

www.regulations.gov. Additional 

instructions for visiting the docket, 

along with more information about 

dockets generally, is available at https:// 

www.epa.gov/dockets. 

FOR FURTHER INFORMATION CONTACT: For 

technical information contact: Renee 

Beardslee, New Chemical Division 

(7405M), Office of Pollution Prevention 

and Toxics, Environmental Protection 

Agency, 1200 Pennsylvania Ave. NW, 

Washington, DC 20460–0001: telephone 

number: (202) 564–8787; email address: 

beardslee.renee@epa.gov. 

For general information contact: The 

TSCA-Hotline, ABVI-Goodwill, 422 

South Clinton Ave., Rochester, NY 

14620; telephone number: (202) 554– 

1404; email address: TSCA-Hotline@

epa.gov. 

SUPPLEMENTARY INFORMATION: 

I. Does this action apply to me? 

This action is directed to the public 

in general. This notice may be of 

specific interest to persons who are or 

may be interested in risk assessments of 

new chemical substances under TSCA 

(e.g., submitters of TSCA 5 notices, 

industry, non-governmental 

organizations (NGOs), and academia). 

Since other entities may also be 

interested, the Agency has not 

attempted to describe all the specific 

entities that may be affected by this 

action. 

II. What action is the Agency taking? 

EPA is announcing the availability of 

a new decision framework for use by the 

New Chemicals Division (NCD) of the 

Office of Pollution Prevention and 

Toxics (OPPT) for identification of eye 

irritation or corrosion hazards for new 

chemical substances based on 

prioritization of reproducible, humanrelevant data. The document supports 

EPA’s efforts to develop NAMs that do 

not require vertebrate animal testing and 

furthers the agency’s commitment to 

reduce and replace the use of vertebrate 

animals in the testing of chemical 

substances and mixtures. 

TSCA section 4(h)(2)(A) directs EPA 

to ‘‘promote the development and 

implementation of alternative test 

methods and strategies to reduce, refine, 

or replace vertebrate animal testing and 

provide information of equivalent or 

better scientific quality and relevance 

for assessing risks of injury to health or 

the environment.’’ 

To incorporate alternative test 

methods and strategies, or NAMs, data 

for eye irritation and corrosion hazard 

identification into the new chemicals 

program risk assessment process, NCD 

developed a framework for new 

chemical risk assessments that 

prioritizes reproducible, humanrelevant in vitro data. The Framework is 

based upon existing peer-reviewed 

literature, accepted Organization for 

Economic Cooperation and 

Development (OECD) test guidelines, 

and other existing accepted risk 

assessment approaches. 

NCD is responsible for conducting 

risk assessments for new chemical 

substances submitted under TSCA 

section 5 authority. NCD expects 

multiple benefits from the incorporation 

of this proposed Framework in its 

assessment including: (1) progress 

towards fulfilling TSCA section 4(h)(2) 

statutory requirements; (2) transparency 

for stakeholders regarding EPA’s process 

of hazard identification of eye irritation 

and corrosion for new chemical 

submissions; (3) clear scientific 

rationale for identification of eye 

irritation and corrosion hazards for 

human health assessors leading to 

improved consistency across final new 

chemical risk assessments; and (4) use 

of the most reproducible, humanrelevant scientific data for decisionmaking. 

III. Does this Framework impose 

binding requirements? 

This document is not binding on the 

Agency or any outside parties, and the 

Agency may depart from it where 

circumstances warrant and without 

prior notice. While EPA has made every 

effort to ensure the accuracy of the 

discussion in the Framework, the 

obligations of EPA and the regulated 

community are determined by statutes, 

regulations, or other legally binding 

documents. In the event of a conflict 

between the discussion in the 

Framework document and any statute, 

regulation, or other legally binding 

document, the Framework document 

will not be controlling. 

IV. Is this Framework subject to the 

Paperwork Reduction Act (PRA)? 

This action does not contain any new 

or revised information collections or 

burden subject to additional OMB 

approval under the PRA, 44 U.S.C. 3501 

et seq. Burden is defined in 5 CFR 

1320.3(b). Information collection 

activities contained in the TSCA new 

chemicals program are already approved 

by OMB under the PRA and are 

assigned OMB Control No. 2070–0038 

(EPA ICR No. 1188.14). 

Authority: 15 U.S.C. 2604 et seq. 

Dated: January 3, 2024. 

Michal Freedhoff, 

Assistant Administrator, Office of Chemical 

Safety and Pollution Prevention. 

[FR Doc. 2024–00169 Filed 1–8–24; 8:45 am] 

BILLING CODE P 

FEDERAL DEPOSIT INSURANCE 

CORPORATION 

Sunshine Act Meetings 

TIME AND DATE: 9:30 a.m. on Friday, 

January 5, 2024. 

PLACE: The meeting was held via video 

conference on the internet. 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: The Special 

Review Committee of the Federal 

Deposit Insurance Corporation met to 

consider matters related to the 

Corporation’s corporate activities within 

its authority to act on behalf of the 

Federal Deposit Insurance Corporation. 

In calling the meeting, the Special 

Review Committee determined, by the 

unanimous vote of Director Jonathan P. 

McKernan and Director Michael J. Hsu 

(Acting Comptroller of the Currency), 

that Corporation business required its 

consideration of the matters which were 

to be the subject of this meeting on less 

than seven days’ notice to the public; 

that no earlier notice of the meeting was 

practicable; that the public interest did 

not require consideration of the matters 

in a meeting open to public observation; 

and that the matters could be 

considered in a closed meeting by 

authority of subsections (c)(2) and (c)(4) 

of the ‘‘Government in the Sunshine 

Act’’ (5 U.S.C. 552b(c)(2) and (c)(4)). 

CONTACT PERSON FOR MORE INFORMATION: 

Requests for further information 

concerning the meeting may be directed 

to Debra A. Decker, Executive Secretary 

of the Corporation, at 202–898–8748. 

Dated: January 5, 2024. 

Federal Deposit Insurance Corporation. 

James P. Sheesley, 

Assistant Executive Secretary. 

[FR Doc. 2024–00333 Filed 1–5–24; 4:15 pm] 

BILLING CODE 6714–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices 1095 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in the BHC Act 

(12 U.S.C. 1842(c)). 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than February 7, 2024. 

A. Federal Reserve Bank of Atlanta 

(Erien O. Terry, Assistant Vice 

President) 1000 Peachtree Street NE, 

Atlanta, Georgia 30309; Comments can 

also be sent electronically to 

Applications.Comments@atl.frb.org]: 

1. Eureka Investor Group, Inc., 

Birmingham, Alabama; to become a 

bank holding company by acquiring 

Eureka Homestead Bancorp, Inc., a 

savings and loan holding company, and 

thereby indirectly acquire Eureka 

Homestead, a savings association 

subsidiary, both of Metairie, Louisiana. 

In addition, Eureka Homestead Bancorp, 

Inc. will convert from a savings and 

loan holding company to a bank holding 

company in connection with Eureka 

Homestead’s conversion from a savings 

association to a national bank. 

Board of Governors of the Federal 

Reserve System. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2024–00166 Filed 1–8–24; 8:45 am] 

BILLING CODE P 

GOVERNMENT ACCOUNTABILITY 

OFFICE 

Request for Medicare Payment 

Advisory Commission (MedPAC) 

Nominations 

AGENCY: U.S. Government 

Accountability Office. 

ACTION: Request for letters of 

nomination and resumes. 

SUMMARY: The Balanced Budget Act of 

1997 established the Medicare Payment 

Advisory Commission (MedPAC) and 

gave the Comptroller General 

responsibility for appointing its 

members. The U.S. Government 

Accountability Office (GAO) is now 

accepting nominations for MedPAC 

appointments that will be effective in 

May 2024. Nominations should be sent 

to the email address listed below. 

Acknowledgement of receipt will be 

provided within a week of submission. 

DATES: Letters of nomination and 

resumes should be submitted no later 

than February 9, 2024, to ensure 

adequate opportunity for review and 

consideration of nominees prior to 

appointment. 

ADDRESSES: Submit letters of 

nomination and resumes to 

MedPACappointments@gao.gov. 

FOR FURTHER INFORMATION CONTACT: 

Gregory Giusto at (202) 512–8268 or 

giustog@gao.gov if you do not receive an 

acknowledgement or need additional 

information. For general information, 

contact GAO’s Office of Public Affairs at 

(202) 512–4800. 

Authority: 42 U.S.C. 1395b–6. 

Gene L. Dodaro, 

Comptroller General of the United States. 

[FR Doc. 2024–00181 Filed 1–8–24; 8:45 am] 

BILLING CODE 1610–02–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

RFA–PS–24–040, Understanding Infant 

Feeding Preferences, Practices, and 

Outcomes for Mothers and other Parents 

with HIV in the United States. 

Date: March 28, 2024. 

Time: 10 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Seraphine Pitt Barnes, Ph.D., M.P.H., 

C.H.E.S., Scientific Review Officer, 

National Center for HIV, Viral Hepatitis, 

STD, and TB Prevention, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–6, 

Atlanta, Georgia 30329–4027. 

Telephone: (770) 488–6115; Email: 

SPittBarnes@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–00214 Filed 1–8–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10398 #43, #45, 

and #48] 

Medicaid and Children’s Health 

Insurance Program (CHIP) Generic 

Information Collection Activities: 

Proposed Collection; Comment 

Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 


khammond on DSKJM1Z7X2PROD with NOTICES